TELA Bio, Inc.

TELA Healthcare Medical Devices

TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 4.49%, EPS grew 9.09%, free cash flow fell 17.7% and total debt rose 35.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

0.98 0.03 −2.97%
Market cap
$45.6M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
3/9
Altman Z
−5.93
Beneish M
−3.31
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 4 3 3

+8 more TTM periods

ROE
1,232.54% (616.62%) (223.35%) 1,654.21%
ROA
(64.71%) (54.15%) (46.23%) (68.06%)
ROIC
(217.11%) (189.96%) (189.70%) (166.17%)
Return on Tangible Assets
(107.46%) (81.93%) (64.90%) (94.46%)
Average Days of Receivables
44.02 43.88 47.05 53.40
Free Cash Flow per Share
(0.55) (0.53) (0.61) (0.69)
Free Cash Flow
(31.62) (30.20) (28.67) (31.50)
Other line items

Show all line items

Columns are period end dates